Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination ProcessPRNewsWire • 05/08/23
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 04/26/23
Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or CancerPRNewsWire • 04/19/23
Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology BusinessPRNewsWire • 04/18/23
Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their IllnessPRNewsWire • 03/23/23
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks OutInvestors Business Daily • 02/16/23
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023PRNewsWire • 02/16/23
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023PRNewsWire • 02/09/23
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/08/23
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal MelanomaPRNewsWire • 01/17/23